These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8951480)

  • 21. Value of and indications for pelvic lymph node dissection in the staging of prostate cancer.
    Middleton RG
    NCI Monogr; 1988; (7):41-3. PubMed ID: 3173502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Complete radical prostatectomy and positive lymph nodes (stages pT1 to 4, N1 to 3, M0, D1)].
    Feyaerts A; Stainier L; Nollevaux MC; De Groote P; Lorge F; Opsomer R; Wese FX; Cosyns JP; Van Cangh P
    Acta Urol Belg; 1998 Mar; 66(1):1-6. PubMed ID: 9611351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
    Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
    Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.
    Weckermann D; Dorn R; Trefz M; Wagner T; Wawroschek F; Harzmann R
    J Urol; 2007 Mar; 177(3):916-20. PubMed ID: 17296375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: results of the first 100 cases.
    Bastide C; Brenot-Rossi I; Garcia S; Rossi D
    Eur J Surg Oncol; 2009 Jul; 35(7):751-6. PubMed ID: 18538526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of pelvic lymphadenectomy in the therapy of prostate and bladder cancer].
    Heidenreich A; Ohlmann CH
    Aktuelle Urol; 2005 Jun; 36(3):219-29. PubMed ID: 16001337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up].
    Isorna Martínez de la Riva S; Belón López-Tomasety J; Marrero Domínguez R; Alvarez Cruz E; Santamaría Blanco P
    Arch Esp Urol; 2004 Sep; 57(7):679-92. PubMed ID: 15536949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy.
    Cadeddu JA; Partin AW; Epstein JI; Walsh PC
    Urology; 1997 Aug; 50(2):251-5. PubMed ID: 9255297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of surgical margin status for biochemical recurrence following radical prostatectomy.
    Hashimoto K; Masumori N; Takei F; Fukuta F; Takahashi A; Itoh N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2008 Jan; 38(1):31-5. PubMed ID: 18203710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy?
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Aug; 12(8):739-44. PubMed ID: 16174048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?
    Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
    Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy.
    Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
    Eur Urol; 2008 Aug; 54(2):344-52. PubMed ID: 18511183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pathological stage T3 prostate cancer after radical prostatectomy: a retrospective study of 246 cases].
    Roche JB; Malavaud B; Soulié M; Cournot M; Gamé X; Mazerolles C; Bachaud JM; Plante P; Rischmann P
    Prog Urol; 2008 Oct; 18(9):586-94. PubMed ID: 18986631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.